Cargando…
Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma
BACKGROUND: Over the last two decades it has become clear that distinct types of human papillomavirus (HPV), the so-called high-risk types (hrHPV), are the major cause of cervical cancer. The hrHPV-DNA testing has shown excellent performance in several clinical applications from screening to the fol...
Autores principales: | Costa, Silvano, Venturoli, Simona, Origoni, Massimo, Preti, Mario, Mariani, Luciano, Cristoforoni, Paolo, Sandri, Maria Teresa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431402/ https://www.ncbi.nlm.nih.gov/pubmed/25987897 http://dx.doi.org/10.3332/ecancer.2015.528 |
Ejemplares similares
-
HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions
por: Mariani, Luciano, et al.
Publicado: (2016) -
E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective
por: Origoni, Massimo, et al.
Publicado: (2015) -
HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice
por: Origoni, M, et al.
Publicado: (2012) -
In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes—Cervical Adenocarcinoma Study Group (CAS-Group)
por: Giannella, Luca, et al.
Publicado: (2023) -
VIN usual type—from the past to the future
por: Preti, Mario, et al.
Publicado: (2015)